BBOT — BridgeBio Oncology Therapeutics Inc.

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 62
• Website: https://bbotx.com

Latest SEC filings for BBOT

• 4 — 2026-10-23
• EFFECT — 2026-09-11
• EFFECT — 2026-09-09
• POS AM — 2026-09-01
• S-3 — 2026-09-01
• 424B3 — 2026-06-22
• 8-K — 2026-06-22
• 424B3 — 2026-05-13
• 10-Q — 2026-05-12
• 8-K — 2026-05-12

Abrir análisis completo

Educational tool only — not investment advice.